United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

Bristol-Myers

AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff.

3 No-Brainer Stocks to Buy for Under $100 Right Now

Johnson & Johnson

Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported significant gains this year.

3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold

Chevron

Lockheed Martin

Long-term investing is possibly among the most boring things. After identifying a quality stock, it's a matter of holding with patience.

Skip Meme Mania: 3 Undervalued Blue-Chip Stocks for Steady Returns

Realty Income Corp

Simon Property Group

Neos S&P 500 High Income ETF

Cohen & Steers Infrastructure Fund Inc

This week, I added to my positions in CSCO, PFE, and UTF. In the 2nd week of June, the Dividend Harvesting Portfolio generated $21.73 of dividend income. The Dividend Harvesting Portfolio has already generated 65.31% of the total dividend income from 2023.

Dividend Harvesting Portfolio Week 172: $17,200 Allocated, $1,532.26 In Projected Dividends

Walmart

You can make your money work for you by investing in the right stocks. One of them is dividend stocks but you do not want to bet your money on companies that have irregular dividend payments or are less reliable.

3 Underrated Dividend Stock Machines to Turbocharge Your Income

AbbVie

British American Tobacco

Disney

JPMorgan Chase & Co

Starbucks

While investing, the focus is on the top blue-chip stocks to buy that offer growth with stability. It is vital to comprehend the fundamentals that characterize these superior stocks.

7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027

Aberdeen Income Credit Strategies Fund

AGNC Investment

ARMOUR Residential REIT

Franklin Resources

Eagle Point Credit

EPR Properties

Yieldmax Meta Option Income Strategy Etf

Oxford Lane Capital

Ready Capital Corp

Sirius XM Holdings Inc

AT&T

Triplepoint Venture Growth BDC

TotalEnergies SE

Verizon

Prior to May 31, 2024, my Readers mentioned 37 equities in their comments on my articles. Some bad-news investments (Rogues) mixed with (mostly) Favorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated top net gain ReFa/Ro: T, VZ, PFE, BEN, EPR, CVX, FBY, TTE, ORC, and RC averaged 23.58% net gains from reader data collected 6/14/24. Ten analyst-target-augured May top price upside reader faves & rogues (ReFa/Ro) were: O, ORI, EPR, T, VZ, PFE, BEN, RC, CVX & TTE, boasting a 16.05% average target price upside estimate.

Readers Identify 29 Ideal May Dividend Buys

High-yield dividend stocks can be potent long-term value creators. Pharma titans Pfizer and Bristol Myers Squibb sport two of the highest yields within their peer group.

Better High-Yield Dividend Stock: Pfizer vs. Bristol Myers Squibb

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Inf.

Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

Pfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19 vaccines faded globally. It was trading at $28 on Monday, down from the pandemic high of $55.56.

Pfizer stock price analysis: how PFE became a fallen angel

Pfizer's stock initially showed signs of recovery, but then stagnated while the rest of the market continued to grow. However, I expect a recovery in the medium term. The Company's Q1 results showed strong performance in non-COVID products and cost-saving measures, leading to analyst sentiment improvement. The recent Wall Street earnings estimates indicate that the Street expects PFE to bottom out in FY2024 in terms of EPS and that fundamentals will then rebound.

Pfizer Stock: The Reversal Should Keep Going

The state of Kansas has filed a lawsuit against Pfizer alleging the company misled the public about the safety and effectiveness of its COVID-19 vaccine including by working to censor critical information on social media.

Kansas sues Pfizer, saying it misled the public over COVID-19 vaccine

The lawsuit claims that, beginning shortly after the vaccine's rollout in early 2021, Pfizer concealed evidence that the shot was linked to pregnancy complications, including miscarriage, as well as inflammation in and around the heart.

Pfizer sued by Kansas for allegedly hiding COVID vaccine risks, making false claims

The U.S. state of Kansas on Monday sued Pfizer , accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.

Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit

BioNTech SE

BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.

Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?

The state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its COVID-19 vaccine.

Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading Claims

Pfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period.

Will Pfizer Stock Rebound To Its 2021 Highs Of $60?

CVS Health

Pfizer stock has been beaten down so far that it offers a dividend yield above 6% at recent prices. Bristol Myers Squibb has been trading for the low multiple of about 7 times trailing free cash flow.

3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade

Pfizer's recent financial performance has some investors questioning its future. The critics aren't entirely wrong -- the pharmaceutical giant does face challenges.

Is It Too Late to Buy Pfizer Stock?

Medifast

Weightwatchers International Inc.

Novo Nordisk's (NYSE: NVO ) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest mega-blockbuster drug. Yet, while you may be thinking about ways to capitalize on its popularity and the rise of other glucagon-like peptide-1 (GLP-1) weight loss treatments, you should also consider the stocks to sell because of this trend.

3 Stocks to Sell as Ozempic Surges in Popularity

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial. These data from MagnetisMM-3 will be presented during a poster session (#932) at the European Hematology Association (E.

ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma

Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.

Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal

News for Pfizer Stock (PFE)